Direct oral anticoagulants (DOACs) have been established and already registered for
clinical use on a wide basis in the United States and Europe. Different from the vitamin K …

Direct oral anticoagulants (DOACs) have been established and already registered
worldwide for clinical use. Contrary to vitamin K antagonists, their mode of action is based …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

A new generation of antithrombotic agents, which are conventionally known as direct oral
anticoagulants (DOACs), have recently emerged and are continuing to be developed. These …

Because their anticoagulant effect is dose predictable, steady, and little influenced by diet
and drugs, laboratory monitoring was deemed unnecessary in trials on venous and arterial …

BACKGROUND The new oral anticoagulants (NOAs) dabigatran, rivaroxaban, and
apixaban have proved effective and safe when used in clinical trials, without a need to …

Sažetak Direct oral anticoagulants (DOACs) represent a new generation of drugs that have
been increasingly used in the prevention and treatment of thromboembolic states. According …

Traditionally, anticoagulant therapy has been conducted through the administration of
vitamin K antagonists (VKAs) and parenteral alternatives. Direct Oral Anticoagulants …

Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and
provide advantages over existing agents. As with all anticoagulants, management protocols …